Kristen Reilly
Senior Director, Channel Access
专长:
Kristen Reilly leads EVERSANA’s Channel Access products, including in-depth analysis of key market trends, growth strategies, and innovations that impact biopharmaceutical strategic accounts. Kristen has 20+ years of experience studying all facets of U.S. managed care and is particularly interested in the intersection of consumerism, analytics, value-based care, and digital health.
Prior to joining EVERSANA, Kristen was a Senior Director at Pointe Advisory, a boutique strategic advisory firm, where she sold, managed, and produced custom insights for leading healthcare payers, GPOs, technology vendors, and investment groups. Recent engagements involved guiding a national payer’s go-to-market strategy in medical and pharmacy benefit designs, optimizing a Medicare Advantage client’s use of aggregators for lead generation, developing a market entry strategy for State Medicaid, and arming a healthcare software vendor’s sales force with competitive battlecards.
Kristen received her BS in Business from Wake Forest University.
Articles by Kristen Reilly
VOICE OF THE CUSTOMER: Payer Pharmacy Directors Report ‘Back-to-Basics’ Contracting, Product Updates, and Pipeline Forecasts Drive Pharma Company Perceptions
Noticeable improvements in several relationship competencies separate the top companies from the rest of the industry. Post-pandemic industry dynamics have forced a shift in the way pharmaceutical companies call on their managed care customers. This past month, NAVLIN Insights concluded our annual research with payer pharmacy directors assessing their relationships and interactions with the pharmaceutical […]
Delivering Value to Leading Payers
Assessment of Strategic Priorities, Competitive Dynamics, and Innovations Impacting Biopharma Access Seven leading payers represent nearly half of all US medical lives and 54% of pharmacy lives: UnitedHealth Group CVS Health, Cigna Elevance Health Kaiser Permanente Humana Centene As these organizations evolve their business models and ultimately their approaches to care and drug management, biopharma […]